Global nuclear medicine firm Curium and biotechnology firm RadioMedix have announced an exclusive agreement to develop and commercialize copper-64 (Cu-64) DOTATATE, an investigational PET diagnostic agent for patients with suspected neuroendocrine tumors.
RadioMedix is currently engaged in phase III clinical trials of the agent and expects to file a new drug application with the U.S. Food and Drug Administration (FDA) in 2019. The partnership builds upon the initial development work conducted by RadioMedix and will benefit from Curium's regulatory, manufacturing, distribution, and commercial expertise, according to the firms.
